首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   42838篇
  免费   3467篇
  国内免费   106篇
耳鼻咽喉   663篇
儿科学   1588篇
妇产科学   1289篇
基础医学   5668篇
口腔科学   1007篇
临床医学   4089篇
内科学   9733篇
皮肤病学   870篇
神经病学   4227篇
特种医学   1461篇
外国民族医学   4篇
外科学   5895篇
综合类   648篇
一般理论   54篇
预防医学   3270篇
眼科学   835篇
药学   2337篇
中国医学   17篇
肿瘤学   2756篇
  2022年   301篇
  2021年   959篇
  2020年   543篇
  2019年   843篇
  2018年   958篇
  2017年   695篇
  2016年   750篇
  2015年   894篇
  2014年   1234篇
  2013年   1593篇
  2012年   2274篇
  2011年   2402篇
  2010年   1325篇
  2009年   1089篇
  2008年   1966篇
  2007年   2020篇
  2006年   1994篇
  2005年   1842篇
  2004年   1732篇
  2003年   1600篇
  2002年   1600篇
  2001年   1154篇
  2000年   1206篇
  1999年   1030篇
  1998年   422篇
  1997年   355篇
  1996年   360篇
  1995年   327篇
  1994年   318篇
  1993年   347篇
  1992年   900篇
  1991年   838篇
  1990年   708篇
  1989年   758篇
  1988年   697篇
  1987年   721篇
  1986年   663篇
  1985年   691篇
  1984年   563篇
  1983年   481篇
  1982年   322篇
  1980年   278篇
  1979年   466篇
  1978年   320篇
  1977年   274篇
  1976年   294篇
  1975年   283篇
  1974年   310篇
  1973年   306篇
  1972年   274篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Introduction: Percutaneous renal mass biopsy has evolved over the last decade with improvements on previous pitfalls including low tissue yield, high non-diagnostic rates, and complications. As understanding of tumor biology and natural history of renal cortical neoplasms has improved, percutaneous renal mass biopsy is poised to have an expanding role in an area characterized by individualized management and refined risk stratification.

Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.

Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings.  相似文献   

3.
4.
5.
6.
Objective: To determine whether packed red blood cell (PRBC) transfusion affects post-prandial superior mesenteric artery blood flow velocities (SMA BFVs) in very-low birth weight (VLBW) neonates and if so, at what time point after transfusion restoration of previous SMA BFV patterns occurs.

Design/Methods: VLBW pre-term neonates, older than 14 days and tolerating bolus enteral feedings administered every 3?h were enrolled in this prospective observational study. Pulsed Doppler ultrasound was used to measure pre- and post-prandial (at 45?min) time-averaged mean, peak and end diastolic velocities (TAMV, PSV, EDV) immediately before and after 15?ml/kg of PRBC transfusion was given over 3?h; patent ductus arteriosus (PDA) status was also evaluated. Subsequent pre- and post-prandial SMA BFVs were recorded 24 and 48?h after the transfusion.

Results: Pre- and post-prandial measurements were obtained for 21 out of 25 enrolled infants. Post-prandial SMA BFVs were attenuated during the feedings immediately after transfusion; at 24 and 48?h after transfusion, changes in post-prandial SMA BFVs were similar to those measured prior to transfusion; the presence of the PDA did not affect results.

Conclusions: PRBC transfusion blunted SMA BFV responses to feedings immediately after the transfusion with normalization observed 24?h post-transfusion.  相似文献   
7.
8.
9.
10.

Background

Payers frequently rely on budget impact model (BIM) results to help determine drug coverage policy and its effect on their bottom line. It is unclear whether BIMs typically overestimate or underestimate real-world budget impact.

Objective

We examined how different modeling assumptions influenced the results of 6 BIMs from the Institute for Clinical and Economic Review (ICER).

Study Design

Retrospective analysis of pharmaceutical sales data.

Methods

From ICER reports issued before 2016, we collected estimates of 3 BIM outputs: aggregate therapy cost (ie, cost to treat the patient population with a particular therapy), therapy uptake, and price. We compared these against real-world estimates that we generated using drug sales data. We considered 2 classes of BIM estimates: those forecasting future uptake of new agents, which assumed “unmanaged uptake,” and those describing the contemporaneous market state (ie, estimates of current, managed uptake and budget impact for compounds already on the market).

Results

Differences between ICER's estimates and our own were largest for forecasted studies. Here, ICER's uptake estimates exceeded real-world estimates by factors ranging from 7.4 (sacubitril/valsartan) to 54 (hepatitis C treatments). The “unmanaged uptake” assumption (removed from ICER's approach in 2017) yields large deviations between BIM estimates and real-world consumption. Nevertheless, in some cases, ICER's BIMs that relied on current market estimates also deviated substantially from real-world sales data.

Conclusions

This study highlights challenges with forecasting budget impact. In particular, assumptions about uptake and data source selection can greatly influence the accuracy of results.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号